ArticleBritish journal of clinical pharmacology2026
Can a population pharmacokinetics model built on intermittent infusions accurately predict meropenem concentrations in children receiving continuous infusions?
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Achieving therapeutic antibiotic levels during intermittent dosing of meropenem and piperacillin-tazobactam in critically ill children: the ATACC study.Antimicrobial agents and chemotherapy · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We previously developed a population pharmacokinetic (PopPK) model using data from paediatric intensive care unit patients receiving meropenem as intermittent infusions. This study assessed the predictive performance of our model in estimating steady-state concentrations of meropenem in paediatric patients receiving continuous infusions. Retrospective data from 57 patients and 163 samples were used to measure bias and precision in both population and individual meropenem concentration predictions via median prediction error (MDPE) and median absolute prediction error (MDAPE), respectively. Error metrics for population predictions were 17.0% MDPE and 33.4% MDAPE, and for individual predictions were 4.4% MDPE and 19.6%, nearly all meeting the commonly used acceptable values of 20% for bias metrics and 30% for precision. In conclusion, this meropenem PopPK model can guide initial dosing strategies and be applied for model-informed precision dosing in critically ill paediatric patients receiving meropenem as continuous infusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.